Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated ... PhD (Co-Founder & CEO), a former senior executive at AbbVie with expertise in drug ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated ... PhD (Co-Founder & CEO), a former senior executive at AbbVie with expertise in drug ...

The creation of AbbVie In 2011 ... rather than being in hospital. The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting ...

Gain insight on Rigel Pharmaceuticals, AbbVie and more in the latest Market Talks covering the Health Care sector.

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

AbbVie held off on launch until it also got the green ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement ...

The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

Global Regenerative Medicine Market is valued at approximately USD 34.56 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 32.4% over the forecast period 2024-2032.